FindTrial
Sign In

Aspirin 325mg

DRUG10 trials

Sponsors

Hennepin Healthcare Research Institute, Jessica Harder, Massachusetts General Hospital, University of Utah, NYU Langone Health

Conditions

Anticoagulant-induced BleedingBody WeightBone MetastasesBone SarcomaDepressionDepressive DisorderEffect of DrugFallopian Tube Cancer

Early Phase 1

Using Aspirin to Improve Immunological Features of Ovarian Tumors
RecruitingNCT05080946
H. Lee Moffitt Cancer Center and Research InstituteFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2021-11-02End: 2026-12-01Target: 100Updated: 2026-04-01

Phase 1

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects
CompletedNCT05166096
Rhoshan Pharmaceuticals IncHealthy
Start: 2021-12-03End: 2022-05-11Updated: 2022-06-14

Phase 2

Aspirin and Antiretroviral Therapy in HIV Infected Patients
TerminatedNCT00783614
Hennepin Healthcare Research InstituteHIV Infection
Start: 2008-10-31End: 2010-06-30Updated: 2017-11-21
Salicylic Augmentation in Depression
TerminatedNCT03152409
Jessica HarderDepression, Depressive Disorder, Major Depressive Disorder +1
Start: 2018-11-15End: 2021-02-16Updated: 2024-01-31
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
CompletedNCT04062032
University of UtahMelanoma (Skin)
Start: 2016-09-27End: 2019-02-27Updated: 2022-02-18
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
CompletedNCT04066725
University of UtahMelanoma (Skin)
Start: 2019-07-25End: 2021-03-19Updated: 2022-02-18

Phase 3

Trial to Determine Effective Aspirin Dose in COPD
RecruitingNCT05265299
Johns Hopkins UniversityPulmonary Disease, Chronic Obstructive
Start: 2023-05-16End: 2026-12-01Target: 48Updated: 2026-03-16

Phase 4

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Enrolling by invitationNCT03244020
Massachusetts General HospitalAnticoagulant-induced Bleeding, Bone Metastases, Bone Sarcoma +4
Start: 2018-02-16End: 2028-07-01Target: 2868Updated: 2025-10-03
Body Weight, Aspirin Dose and Pro-resolving Mediators
CompletedNCT04697719
NYU Langone HealthBody Weight
Start: 2021-11-04End: 2025-01-29Updated: 2026-03-09
PFA 100 Evaluation and Reference Interval HOACNY
Enrolling by invitationNCT06100510
Hematology Oncology Associates of Central New YorkEffect of Drug
Start: 2024-02-19End: 2024-10-10Target: 40Updated: 2024-10-03

Related Papers

A randomized, placebo-controlled crossover trial to assess the influence of body weight on aspirin-triggered specialized pro-resolving mediators: protocol for the discover study
International Journal of Clinical Trials2024-01-24